Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow)

The final quality control of cryopreserved progenitor cells is a successful and persistent three lineage engraftment after transplantation. Of course, the stem cell providing institution is obliged to have a program for controlling and monitoring the manufacturing of cellular therapy products before the patients’ conditioning therapy is started. The FACT-JACIE Standards [1] and the Netcord ⁄ FACT Stan- dards prescribe that the director of the institute shall define tests and procedures for measuring and assaying cellular therapy products to ensure their safety, viability and integ- rity and shall also ensure that products meet predetermined release specifications. This requires specifications of assays and the definition of thresholds to allow release.

[1]  James W. Young,et al.  Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  J. Madrigal,et al.  Quality rather than quantity: the cord blood bank dilemma , 2010, Bone Marrow Transplantation.

[3]  B. Barlogie,et al.  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.

[4]  E. Gluckman,et al.  Cord blood transplantation: state of the art , 2009, Haematologica.

[5]  J. Dipersio,et al.  Improving stem cell mobilization strategies: future directions , 2009, Bone Marrow Transplantation.

[6]  J. Stoltz,et al.  Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility. , 2009, Bio-medical materials and engineering.

[7]  E. Gluckman,et al.  Indications and results of cord blood transplant in children with leukemia , 2008, Bone Marrow Transplantation.

[8]  J. Reems,et al.  Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise , 2008, Transfusion.

[9]  H. Kim,et al.  Post‐thaw viable CD34+ cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation , 2007, Vox sanguinis.

[10]  W. V. van Wieringen,et al.  Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries , 2007, Cytometry. Part B, Clinical cytometry.

[11]  J. Wagner,et al.  Issues in the quality of umbilical cord blood stem cells for transplantation , 2005, Transfusion.

[12]  L. Larratt,et al.  Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment , 2005, Bone Marrow Transplantation.

[13]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[14]  R. Lowenthal,et al.  Cryopreserved human haematopoietic stem cells retain engraftment potential after extended (5-14 years) cryostorage. , 2002, Cryobiology.

[15]  M. Bhatia,et al.  Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[16]  E. Wall,et al.  Extensive early apoptosis in frozen–thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation , 2002, Bone Marrow Transplantation.

[17]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[18]  S. Serke,et al.  A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts , 2001, Bone Marrow Transplantation.

[19]  E. Gluckman.  Current status of umbilical cord blood hematopoietic stem cell transplantation. , 2000, Experimental hematology.

[20]  P. Pedrazzoli,et al.  Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Sutherland,et al.  Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. , 1998, Cytometry.

[22]  S. Singhal,et al.  Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. , 1997, Blood.

[23]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.